Table 2.
Association between clinical and serologic variables of PLWHIV and anti-S antibody titres at 28 days since the second dose of mRNA-1273 vaccine.
| Variable | Subjects (n) | Anti-S1 (U/mL) median (IQR) | p-value |
|---|---|---|---|
| Sex* | 0·55 | ||
| Male | 60 | 2746 (1601-6015) | |
| Female | 11 | 2247 (1510-5763) | |
| Age (years)° | 0·46 | ||
| <35 | 17 | 2948 (2105-5349) | |
| 35-50 | 22 | 2644 (1445-5763) | |
| 50-60 | 22 | 2077 (1073-5111) | |
| >60 | 10 | 2915 (1924 -9454) | |
| Antiretroviral therapy° | 0·88 | ||
| NRTI | 63 | 2474 (1566-5763) | |
| InSTI | 54 | 2467 (1546-5171) | |
| NNRTI | 9 | 2683 (1170-12500) | |
| PI | 9 | 2999 (670-6358) | |
| Plasma HIV viral load§ | 71 | ||
| (slope; 95% CI) | (0·66; 0·35,1·26) | 0·20 | |
| CD4+ T cell count per µL° | 0·02 | ||
| <350 per µL | 6 | 2173 (987-4109) | |
| 350-500 per µL | 7 | 5763 (4801-12500) | |
| >500 per µL | 58 | 2449 (1524-5704) | |
| CD4+ T cell count percentage§ | 71 | ||
| (slope; 95% CI) | (0·99; 0·97,1·01) | 0·31 | |
| CD4+ T/CD8 ratio >=1* | 0·14 | ||
| No | 39 | 2948 (1877-6086) | |
| Yes | 32 | 2195 (1492-4478) | |
| CD4+ T/CD8 ratio >=0·4* | 0·68 | ||
| No | 14 | 3746 (1031-6146) | |
| Yes | 57 | 2474 (1575-5111) | |
| Optimal immunologic response†,* | 0·06 | ||
| No | 42 | 3174 (1836-6157) | |
| Yes | 29 | 2143 (1445-3361) | |
| HCV-Ab* | 0·38 | ||
| Negative | 59 | 2490 (1575-5349) | |
| Positive | 5 | 6701 (2644-9274) | |
| HBsAg* | 0·21 | ||
| Negative | 62 | 2702 (1601-6015) | |
| Positive | 2 | 1474 (1071-1877) | |
| Years since diagnosis§ | 69 | ||
| (slope; 95% CI) | (0·99; 0·97,1·01) | 0·38 | |
| (CD4+ T cell count per µL)[2] at nadir§ | 69 | ||
| (slope; 95% CI) | (1·00; 0·89,1·13) | 0·96 | |
| Plasma HIV viral load at zenith§ | 69 | ||
| (slope; 95% CI) | (1·03; 0·73,1·46) | 0·86 | |
| AIDS diagnosis* | 0·50 | ||
| No | 31 | 2579 (1794-6086) | |
| Yes | 19 | 2721 (1031-5349) | |
| CMV IgG* | 0·96 | ||
| Negative | 5 | 2771 (2474-3696) | |
| Positive | 38 | 2475 (1510-5763) | |
| Anti-N* | <0·001 | ||
| Negative | 61 | 2437 (1485-4526) | |
| Positive | 9 | 12500 (5704->12500) |
CI, confidence interval; NRTIs, nucleoside reverse transcriptase inhibitors; InSTIs, integrase strand transfer inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen; CMV, cytomegalovirus; anti-N, anti-nucleocapsid protein.
†
Optimal immunologic response was defined as: CD4+ T/CD8 ratio≥1 plus CD4+ T≥500cells/µL plus CD4+ T%≥30%. Statistics calculated using
⁎
Mann–Whitney U test,
°
Kruskal-Wallis test or
§
Spearman's rank correlation coefficients.